Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Liabilities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Total Liabilities for 7 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 22.64% to $61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.0 million through Dec 2025, up 22.64% year-over-year, with the annual reading at $61.0 million for FY2025, 22.64% up from the prior year.
  • Total Liabilities for Q4 2025 was $61.0 million at 4D Molecular Therapeutics, up from $55.0 million in the prior quarter.
  • The five-year high for Total Liabilities was $61.0 million in Q4 2025, with the low at $14.3 million in Q2 2021.
  • Average Total Liabilities over 5 years is $35.2 million, with a median of $31.1 million recorded in 2022.
  • The sharpest move saw Total Liabilities tumbled 85.59% in 2021, then soared 112.9% in 2022.
  • Over 5 years, Total Liabilities stood at $34.4 million in 2021, then fell by 11.26% to $30.5 million in 2022, then rose by 5.09% to $32.1 million in 2023, then soared by 55.26% to $49.8 million in 2024, then increased by 22.64% to $61.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $61.0 million, $55.0 million, and $52.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.